RxDoctor Payments Data

Paul Gipps, MD

Internal Medicine · Miami, FLNPI 1487745170

Payments from drug & device makers

$1,176in general payments, 2019–2025

Across 49 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$656
  • Exact Sciences$138
  • Lilly USA, LLC$97
  • Amgen$53
  • GSK$48
  • Boston Scientific$35
  • plus $148 from 7 others

What the payments were for

  • Food & beverage$1,176100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,176 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$127,516
Medicare patients
262
Services billed
952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$102,315
OzempicSemaglutide67$71,066
FarxigaDapagliflozin Propanediol32$38,674
JardianceEmpagliflozin18$19,064
XareltoRivaroxaban23$16,574
MounjaroTirzepatide13$13,665
SymbicortBudesonide/Formoterol Fumarate26$9,816
Atorvastatin Calcium352$4,389
Mirtazapine87$3,302
Doxepin Hcl14$3,250
Rosuvastatin Calcium251$3,098
Losartan Potassium176$2,418
Levothyroxine Sodium209$2,408
Amlodipine Besylate248$1,997
Pantoprazole Sodium120$1,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$102,315109 claims
Novo NordiskOzempic$656$71,06667 claims
AstraZenecaFarxiga, Symbicort$23$48,49158 claims
Lilly USA, LLCMounjaro$97$13,66513 claims
AbbVieSynthroid$29$1,37325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →